BioLineRx Ltd.BLRXEarnings & Financial Report
Nasdaq · Health Care · Pharmaceutical Preparations
BioLineRx Ltd., or BioLine, is a publicly traded drug development company. Headquartered in Israel, its shares are traded on the NASDAQ Capital Market and on the Tel Aviv Stock Exchange.
BLRX Q2 FY2024 Key Financial Metrics
Revenue
$5.4M
Gross Profit
$4.5M
Operating Profit
$-5.8M
Net Profit
$484.0K
Gross Margin
83.4%
Operating Margin
-107.0%
Net Margin
9.0%
YoY Growth
N/A
EPS
$0.00
BioLineRx Ltd. Q2 FY2024 Financial Summary
BioLineRx Ltd. reported revenue of $5.4M for Q2 FY2024, with a net profit of $484.0K (up 102.6% YoY) (9.0% margin). Cost of goods sold was $897.0K, operating expenses totaled $10.3M.
Key Financial Metrics
| Total Revenue | $5.4M |
|---|---|
| Net Profit | $484.0K |
| Gross Margin | 83.4% |
| Operating Margin | -107.0% |
| Report Period | Q2 FY2024 |
BioLineRx Ltd. Quarterly Revenue & Net Profit History
BioLineRx Ltd. results over the last 2 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q2 FY2024 | $5.4M | — | $484.0K | 9.0% |
| Q2 FY2023 | $0 | — | $-18.5M | N/A |
Income Statement
| Q2 2023 | Q2 2024 | |
|---|---|---|
| Revenue | $0 | $5.4M |
| YoY Growth | N/A | N/A |
Balance Sheet
| Q2 2023 | Q2 2024 | |
|---|---|---|
| Assets | $58.9M | $64.6M |
| Liabilities | $37.9M | $50.6M |
| Equity | $21.1M | $13.9M |
Cash Flow
| Q2 2023 | Q2 2024 | |
|---|---|---|
| Operating CF | $-17.7M | $-25.4M |